0000947871-12-000526.txt : 20120703
0000947871-12-000526.hdr.sgml : 20120703
20120703151946
ACCESSION NUMBER: 0000947871-12-000526
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120629
FILED AS OF DATE: 20120703
DATE AS OF CHANGE: 20120703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Anthera Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001316175
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 201852016
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
BUSINESS PHONE: (510) 856-5600
MAIL ADDRESS:
STREET 1: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ISALY SAMUEL D
CENTRAL INDEX KEY: 0001055949
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34637
FILM NUMBER: 12944362
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC
CENTRAL INDEX KEY: 0001055951
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34637
FILM NUMBER: 12944361
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: OrbiMed Capital GP IV LLC
CENTRAL INDEX KEY: 0001502240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34637
FILM NUMBER: 12944360
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 212-739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
ss148155_4.xml
OWNERSHIP DOCUMENT
X0306
4
2012-06-29
0
0001316175
Anthera Pharmaceuticals Inc
ANTH
0001055951
ORBIMED ADVISORS LLC
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK
NY
10022
1
0
0
0
0001502240
OrbiMed Capital GP IV LLC
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK
NY
10022
1
0
0
0
0001055949
ISALY SAMUEL D
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK
NY
10022
1
0
0
0
Common Stock
2012-06-29
4
S
0
1283300
0.7341
D
0
I
See Footnotes
The shares of Common Stock ("Shares") reported herein as indirectly beneficially owned by OrbiMed Capital GP IV LLC ("OrbiMed Capital"), OrbiMed Advisors LLC ("OrbiMed Advisors") and Samuel D. Isaly ("Isaly") are directly owned by OrbiMed Private Investments IV, LP ("OPI IV") and each of OrbiMed Capital, OrbiMed Advisors and Isaly may be deemed to have a pecuniary interest in Shares beneficially owned by OPI IV. This Form 4 is being jointly filed by OrbiMed Capital, OrbiMed Advisors and Isaly.
OrbiMed Capital is the sole general partner of OPI IV. OrbiMed Advisors is a registered adviser under the Investment Advisers Act of 1940, as amended, and the sole managing member of OrbiMed Capital. OrbiMed Advisors and OrbiMed Capital may be deemed to have beneficial ownership of the Shares reported herein by virtue of such relationships and the authority of OrbiMed Capital to direct the vote and disposition of the Shares held by OPI IV. Isaly, a natural person, may be deemed to have beneficial ownership of the Shares reported herein in his capacity as the holder of a controlling interest in OrbiMed Advisors.
Each of OrbiMed Advisors, OrbiMed Capital and Isaly disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $0.6760 to $0.7700, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote
/s/ Samuel D. Isaly
2012-07-03